[ad_1]
News and research before it hits the news on CNBC and more. Claim your 1 week free trial Street Insider Premium here.
CALGARY, Alberta–(Newsfile Corp. – April 3, 2023) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0)(“Hemostemics” or “company“) is pleased to announce that it has completed a second round of interviews with potential candidates for the position of Executive Vice President of Business Development. EVP Business Development is a team focused on: Responsible for building and leading the
- Sold Tranch 1 – 500 ACP processed convertible notes for US$35,000 each, raising US$17.5 million. Then sell tranche 2 and so on to raise funds for production.
- We are launching a rollup of US-based podiatry clinics.
- Show podiatrists the impact of adding waived ACP-01 treatment on clinic revenues and margins. For example, we model the sale of sterile CLI infusion procedures up to 16 ACP per day for 30 min according to the Phase II infusion protocol.
- Sell and shut down podiatrist on how podiatrist monetizes the value of sweat stock and exchanges it for Hemostemix stock.
- It analyzes market access in the EU, Mexico, Latin America, Middle East, India, Japan, and South Korea to provide direction and analysis for potential Podiatry Clinics global acquisitions.
- Hire and manage a well-defined, multi-lingual, biotech-savvy business development sales executive to accelerate podiatry clinic acquisitions and compassionate sales of ACP.
The 5-year survival rate for CLI amputees is
ACP-01 has completed a Phase II clinical trial in CLI. In a 17-center phase II clinical trial of his 68 subjects randomized 2:1 to receive ACP, 93.5% of his limbs treated with ACP-01 were saved from amputation. was broken. UBC and U of T Presented Interim Data Points from Phase 2 Study Showed Ulcer Healing and Ischemic Resting Pain Resolution in 10 of 12 Patients with Results Maintained for Up to 4.5 Years it was done.
In the ACP-01 randomized phase 1 trial of 20 subjects followed for 2 years, there were no deaths and 70% (7/10) of the treated extremities were saved from amputation. In the control group (untreated), 2 of her died and 75% (6/8) had amputations.
The annual incidence of CLI is estimated at 220–3,500 per 1,000,000 and its prevalence is estimated at 1% of the adult population (CLI epidemiology and clinical manifestations). It is estimated that 236 million people suffer from peripheral arterial disease (PAD) and up to 10% of PAD patients progress to his CLI (23,600,000). Hemostemix is expanding its patented automated cell therapy system (“ACTS production”) to 4,000 batches per month by the end of 2027, optimizing costs and margins while completing clinical trials. to meet demand.
ACP-01 as a treatment for heart disease (ischemic cardiomyopathy) was studied in 245 patients (171 subjects) in 1 of 3 phase 1 trials or ongoing for ischemic cardiomyopathy. showed statistically significant improvement in the 245 patients (74 subjects) studied who received compassionate treatment for retroactively. In a retrospective study, left ventricular ejection fraction, a key indicator of heart health, improved by an average of 27% 12 months after treatment ($9 billion.
About Hemostemix
Hemostemix is a patient blood-sourced stem cell therapy platform containing angiogenic, neuronal, and cardiomyocyte progenitors. Founded in 2003 and a recipient of the World Economic Forum’s Technology Pioneer Award, the company develops, patents and manufactures 4,000 patient treatments per month in the manufacture of automated cell therapy systems (“ACTS”). Scale up by the end of 2027. cell. ACP-01 is made from the patient’s blood. Six published studies of ACP-01 and a retrospective study of 53 continuously treated patients with ischemic cardiomyopathy, a total of 345 study participants, found that ACP-01 was associated with severe ischemia. It has shown safety and preliminary efficacy in the treatment of limb, angina, ischemic and dilated cardiomyopathy. The Company is offering forward sales of ACP-01 on a preferential basis (see press release dated March 7).th) while completing clinical trials to obtain exclusive market access for certain medical indications. For more information, please visit www.hemostemix.com.
For more information, please contact:
Thomas Smeenk, President, CEO, Co-Founder
EM: [email protected]
Phone: 905-580-4170
Neither TSX Venture Exchange nor its regulated service providers (as those terms are defined in the TSX Venture Exchange Policy) are responsible for the adequacy or accuracy of this release..
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. All statements other than statements of historical fact contained herein are forward-looking information. Specifically, this news release contains information regarding the Company’s funding of its flagship product, ACP-01, and future prospects related to the commercialization of ACP-01 through the sale of humanitarian treatments exempt from regulatory approval. Contains information. There is no assurance that such forward-looking information will be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix’s current beliefs and is based on information currently available to Hemostemix and assumptions Hemostemix believes to be reasonable. These assumptions include, but are not limited to: The underlying value of Hemostemix and its common stock. Successful settlement of litigation pursued or defended by Hemostemix (“lawsuit“); results of studies, tests, studies, and analyzes of ACP-01 (including analyzes equivalent to or better than previous studies, tests, or studies); and all regulatory authorities required for the study, test, or study. the level of activity in the healthcare sector; market acceptance and market trends; general economics; consumer interest in Hemostemix’s services and products; competition and Hemostemix’s competitive advantage; has received sufficient funding to fund Hemostemix’s operations, including, but not limited to, trials, research and litigation. Forward-looking information is subject to known and unknown risks, uncertainties and Hemostemix’s actual Subject to other factors that may cause our results, level of activity, performance or outcomes to differ materially from those expressed or implied by such forward-looking information, risks and other factors. In order to obtain regulatory approval for a Phase II or Phase III clinical trial of ACP-01, Hemostemix will complete the clinical trial, complete a satisfactory analysis, and submit the results of such analysis. the possibility of litigation the Hemostemix mayface general business, economic, competitive, political and social uncertainties general capital market conditions and securities market prices;delayed or failed board or regulatory approval;actual results of future operations, including actual results of future studies, trials or studies;competitions;changes in law affecting Hemostemix;acceptable conditions; Timing and availability of external funding in 2020. Long-term capital requirements and future developments in Hemostemix’s market and expected markets to compete in. Lack of qualified and skilled workers, or loss of key personnel. -19 Pandemic-related risks include travel restrictions, border closures, non-essential business closures, service interruptions, quarantines, self-isolation, shelters, and other recommendations, orders from government authorities seeking to limit the pandemic. , and measures include: – location and social distancing, market disruptions, economic activity and funding disruptions, supply chain and distribution channel disruptions, and possible domestic or global recession or recession; a deterioration in general economic conditions, including; the potential impact of COVID-19; a pandemic could occur to Hemostemix, including reduced demand for services provided by Hemostemix; Deteriorating financial markets may also limit Hemostemics’ ability to raise external funding. A description of additional risk factors that could cause actual results to differ materially from the forward-looking information is set forth in his Hemostemix disclosure document on the SEDAR website www.sedar.com. Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information and cannot identify any factors that could cause results to differ from those anticipated, estimated or intended. There may be other factors that make Readers are cautioned that the list of factors mentioned above is not exhaustive. Readers are cautioned not to place undue reliance on forward-looking information. Because there can be no guarantee that the plans, intentions or expectations on which they are placed will come true. Any forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents his Hemostemix forecasts as of the date of this news release and, therefore, is subject to change after that date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws. categorically deny.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/161035.
[ad_2]
Source link